The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies.

• Comprehensive directory of diagnostic deals since 2007
• Diagnostic contract documents
• Diagnostic agreement terms
• Diagnostic agreement structure
• Top diagnostic deals by value
• Most active diagnostic dealmakers

The Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all diagnostics partnering deals announced since January
2007, including financial terms where available, including over 3,000 links to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of diagnostics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diagnostics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading diagnostics deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of diagnostics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of diagnostics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and
specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in diagnostics
partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of diagnostics technologies and products.

Report scope

Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the diagnostic trends and structure of deals entered into by leading companies worldwide.

Diagnostics Partnering Terms and Agreements includes:

• Trends in diagnostic dealmaking in the biopharma industry since 2007
• Analysis of diagnostic deal structure
• Case studies of real-life diagnostic deals
• Access to over 2,900 diagnostic contract documents
• The leading diagnostic deals by value since 2007
• Most active diagnostic dealmakers since 2007
• The leading diagnostic partnering resources

In Diagnostics Partnering Terms and Agreements , the available contracts are listed by:

• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target

Each deal title links via Weblink to online deal records of actual diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. .

Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:

• In-depth understanding of diagnostic deal trends since 2007
• Analysis of the structure of diagnostic agreements with numerous real life case studies
• Comprehensive access to over 2,900 actual diagnostic contracts entered into by the world’s biopharma companies
• Detailed access to actual diagnostic contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a diagnostic agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary 

Chapter 1 – Introduction

Chapter 2 – Trends in diagnostic dealmaking

• 2.1. Introduction
• 2.2. Diagnostic partnering over the years
• 2.3. Most active diagnostic dealmakers
• 2.4. Bigpharma diagnostic dealmaking activity
• 2.5. Bigpharma not active in diagnostics
• 2.6. Diagnostics partnering by deal type
• 2.7. Diagnostics partnering by stage of development
• 2.8. Diagnostics partnering by disease type
• 2.9. Average deal terms for diagnostics partnering
• 2.9.1 Diagnostics partnering headline values
• 2.9.2 Diagnostic deal upfront payments
• 2.9.3 Diagnostics royalty rates
• 2.10. The anatomy of diagnostic partnering
• 2.10.1. The anatomy of a diagnostic deal
• 2.10.1.a. Case study 1: Sequenom – Lenetex – January 2007
• 2.10.1.b. Case study 2: Celera – Siemens Medical Solutions – July 2007
• 2.10.1.c. Case study 3: US Genomics – Rosetta Genomics – May 2006
• 2.11. Litigation and settlement in diagnostics

Chapter 3 – Leading diagnostic deals

• 3.1. Introduction
• 3.2. Top diagnostic deals by value
• 3.3. Top diagnostic deals involving bigpharma
• 3.4. Leading diagnostics M&A deals by value

Chapter 4 – Bigpharma diagnostic deals 

• 4.1. Introduction
• 4.2. How to use bigpharma diagnostic partnering deals
• 4.3. Bigpharma partnering company profiles
• Abbott
• Actavis
• Alcon Labs
• Allergan
• Amgen
• Apotex
• Astellas
• AstraZeneca
• Baxter International
• Bayer
• Biogen Idec
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Cephalon
• Chugai
• CSL
• Daiichi Sankyo
• Dainippon Sumitomo
• Eisai
• Eli Lilly
• Forest Laboratories
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• Hospira
• Johnson & Johnson
• Kyowa Hakko Kirin
• Lundbeck
• Menarini
• Merck & Co
• Merck KGaA
• Mitsubishi Tanabe
• Mylan
• Novartis
• Novo Nordisk
• Nycomed Pharma
• Otsuka
• Pfizer
• Roche
• Sanofi
• Servier
• Shionogi
• Shire
• Stada
• Takeda
• Teva
• UCB
• Warner Chilcott
• Watson

Chapter 5 – Diagnostic dealmaking directory 

• 5.1. Introduction
• 5.2. By stage of development
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Regulatory
• Marketed
• Formulation
• 5.3. By deal type
• Asset purchase
• Assignment
• Bigpharma outlicensing
• Co-development
• Collaborative R&D
• Co-market
• Contract service
• Co-promotion
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Interests
• Joint venture
• Licensing
• Litigation
• Loan
• Manufacturing
• Manufacturing - OEM
• Marketing
• Material transfer
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub-license
• Supply
• Technology transfer
• Termination
• Warranty
• 5.4. By therapy area
• Cardiovascular
• Central Nervous System
• Dental
• Dermatology
• Gastrointestinal
• Genetic disorders
• Genitourinary
• Hematology
• Hormonal
• Hospital care
• Immunology
• Infectives
• Inflammatory
• Metabolic
• Musculoskeletal
• Oncology
• Ophthalmics
• Respiratory
• Sensory organs

Chapter 6 – Diagnostic partnering resource center

• 6.1. Online diagnostic partnering
• 6.2. Diagnostic partnering events
• 6.3. Further reading on diagnostic dealmaking

Appendices 

Appendix 1 – Deal type definitions
Appendix 2 – Example diagnostics partnering agreement

About CurrentPartnering
Recent titles from CurrentPartnering
Order Form – Reports

Table of figures

• Figure 1: Diagnostic partnering since 2007
• Figure 2: Most active diagnostic dealmakers 2007-2011
• Figure 3: Bigpharma – top 50 – diagnostic deals 2007 to 2011
• Figure 4: Bigpharma diagnostic deal frequency – 2007 to 2011
• Figure 5: Inactive bigpharma in diagnostic dealmaking 2007-2011
• Figure 6: Diagnostics partnering by deal type since 2007
• Figure 7: Diagnostics partnering by stage of development since 2007
• Figure 8: Diagnostics partnering by disease type since 2007
• Figure 9: Diagnostics partnering by oncology target since 2007
• Figure 10: Diagnostic deals with a headline value – by stage of development
• Figure 11: Diagnostic deal headline value distribution – discovery stage, US$million
• Figure 12: Diagnostic deal headline value distribution – discovery stage, US$million - detail
• Figure 13: Diagnostic deal headline value distribution – preclinical stage, US$million
• Figure 14: Diagnostic deal headline value distribution – preclinical stage, US$million
• Figure 15: Diagnostic deals with upfront payment values – by stage of development
• Figure 16: Diagnostic deal upfront payment distribution – discovery stage, US$million
• Figure 17: Diagnostic deal upfront payment distribution – discovery stage, US$million - detail
• Figure 18: Diagnostic deals with milestone payments
• Figure 19: Diagnostic deal milestone payment distribution, US$million
• Figure 20: Diagnostic deals with royalty rates
• Figure 21: Components of the typical diagnostic deal structure
• Figure 22: Settlement licensing agreements since 2003
• Figure 23: Top diagnostic deals by value since 2007
• Figure 24: Top diagnostic deals signed by bigpharma value since 2007
• Figure 25: Top diagnostic M&A deals by value since 2007
• Figure 26: Diagnostic deals by therapy – cardiovascular – 2007 - 2011
• Figure 27: Diagnostic deals by therapy – central nervous system – 2007 - 2011
• Figure 28: Diagnostic deals by therapy – dental – 2007 - 2011
• Figure 29: Diagnostic deals by therapy – dermatology – 2007 - 2011
• Figure 30: Diagnostic deals by therapy – gastrointestinal – 2007 - 2011
• Figure 31: Diagnostic deals by therapy – genetic disorders – 2007 - 2011
• Figure 32: Diagnostic deals by therapy – genitourinary – 2007 - 2011
• Figure 33: Diagnostic deals by therapy – hematology – 2007 - 2011
• Figure 34: Diagnostic deals by therapy – hormonal – 2007 - 2011
• Figure 35: Diagnostic deals by therapy – hospital care – 2007 - 2011
• Figure 36: Diagnostic deals by therapy – immunology – 2007 - 2011
• Figure 37: Diagnostic deals by therapy – infectives – 2007 - 2011
• Figure 38: Diagnostic deals by therapy – inflammatory – 2007 - 2011
• Figure 39: Diagnostic deals by therapy – metabolic – 2007 - 2011
• Figure 40: Diagnostic deals by therapy – musculoskeletal – 2007 - 2011
• Figure 41: Diagnostic deals by therapy – oncology – 2007 - 2011
• Figure 42: Diagnostic deals by therapy – ophthalmics – 2007 - 2011
• Figure 43: Diagnostic deals by therapy – respiratory – 2007 - 2011
• Figure 44: Diagnostic deals by therapy – sensory organs – 2007 - 2011
• Figure 45: Online partnering resources
• Figure 46: Forthcoming partnering events
• Figure 47: Deal type definitions
• Figure 48: Diagnostics partnering agreement between Inhibitex and 3M, February 2007

• $2,695: single-user
• $4,095: multi-user
• $8,095: single site license
• $13,475: global site license

An annual subscription to quarterly updates can be purchased for a small
additional fee; ensuring you are kept up-to-date with the very latest diagnostics
partnering deals. Quarterly updates available from $1,347.50.

A full explanation of license type definitions can be found here.

An additional $500 per copy will be added for full print and CD-ROM requests.